HOW TRANSPARENT IS NH? FOLLOW OUR SCORECARD

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals, Inc. - Common Stock (NQ:AGIO)

31.52 +1.57 (+5.24%)
Delayed Quote Updated: 3:18 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agios Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Q4 2025 Revenue Beat and Narrower Loss ↗
Via Chartmill
News headline image
Retail’s Christmas Eve Watchlist: Omeros, Nike, Citi, Dynavax And Agios Spark Most Market Chatter ↗
The stocks were tracked during the shortened Christmas Eve session across healthcare, consumer, and banking. 
Via Stocktwits
Topics ETFs Economy Stocks
News headline image
Here's Why Shares in Agios Pharmaceuticals Popped Today ↗
The company received FDA approval for its leading drug, and investors were pleased with the update from management. 
Via The Motley Fool
News headline image
Which stocks are gapping on Wednesday? ↗
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug ↗
Via Stocktwits
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
Earnings Outlook For Agios Pharmaceuticals ↗
 
Via Benzinga
News headline image
The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy
On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),... 
Via PredictStreet
Topics Economy
News headline image
Why Did AGIO Stock Surge 14% Today? ↗
Agios Pharmaceuticals announced that the FDA approved its oral therapy for anemia in adults with alpha- or beta-thalassemia. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Head Into Christmas Eve With Caution: Why ASTS, DVAX, ABVX, PATH, GOOGL Are On Traders' Radar Today ↗
Markets are moving from a record-setting close into a thin, holiday-shortened Christmas Eve session. 
Via Stocktwits
Topics ETFs Stocks
News headline image
This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
 
Via Benzinga
News headline image
This Bellring Brands Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results
Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of... 
Via MarketMinute
News headline image
Which stocks are moving on Wednesday? ↗
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Why Shares in Agios Pharmaceuticals Got Crushed Today ↗
The company's pivotal Phase 3 trial hit one primary endpoint but missed another. 
Via The Motley Fool
News headline image
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results ↗
 
Via Benzinga
News headline image
Why Is Agios Pharmaceuticals Stock Sinking Today? ↗
Agios stock drops as mitapivat's Phase 3 trial shows strong hemoglobin gains but limited impact on sickle cell pain crises, prompting mixed investor reaction. 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
AGIO Stock Cracks After Sickle-Cell Disease Drug Delivers Mixed Results In Late-Stage Trial ↗
While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance, Agios... 
Via Stocktwits
News headline image
Wondering what's happening in today's pre-market session? ↗
Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tops Q3 2025 Estimates with Strong Revenue Beat ↗
Agios Pharma's Q3 2025 results beat revenue and EPS estimates, driving a positive market reaction and highlighting strong commercial performance. 
Via Chartmill
News headline image
Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment
San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly... 
Via MarketMinute
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO
From Pomerantz LLP
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm
From Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article